Position in GNLX
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$0
-$312,790 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
6 quarters on record
Common Shares in GNLX Over Time
Shares Held
Position Value (USD)
Derivatives in GNLX
reported options exposure · as of Mar 31, 2026CallValue
$29,040
CallShares
12,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026JANE STREET GROUP, LLC holds $1,255,284,514 across 317 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
1,757,672 | $130,524,721 | |
| 2 | RPRX |
Royalty Pharma plc
|
2,400,382 | $115,146,324 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
2,041,669 | $67,824,242 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
122,946 | $54,900,305 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
831,707 | $53,753,223 | |
| 6 | EXEL |
Exelixis, Inc.
|
1,087,030 | $46,622,715 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
223,615 | $42,274,415 | |
| 8 | BNTX |
BioNTech SE
|
336,757 | $29,930,962 |
All Filings in GNLX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $29,040 | 12,000 | Call | Defined | 2026-05-12 | |
| 2025-12-31 | $312,790 | 71,741 | Shares | Defined | 2026-02-12 | |
| 2025-06-30 | $30,921 | 10,774 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $189,666 | 70,247 | Shares | Defined | 2025-05-19 | |
| 2024-06-30 | $142,689 | 73,174 | Shares | Defined | 2024-08-15 | |
| 2023-06-30 | $236,434 | 7,226 | Shares | Defined | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||